Program
HH-006
A development code.
Its studies are mostly in Hepatitis B, Chronic · Hepatitis B, led by Huahui Health.
Furthest: phase 2, since Apr 2, 20263 company-led studies, 1 open or runningNext primary completion: Feb 28, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Huahui Health | 31 open or running | phase 2since Apr 2, 2026 | Mar 2, 2022 | Feb 28, 2028phase 2 · NCT07519330 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 2, 2022First study: phase 1 study in Hepatitis BFirst studyNCT05275465 · 33 enrolled · Australia
- Mar 25, 2026Phase 1 study in Hepatitis B, ChronicNCT07515209 · 36 enrolled · China
- Apr 2, 2026Phase 2 study in Hepatitis B, ChronicPhase 2 reachedNCT07519330 · 45 planned · China
Ahead
- Feb 28, 2028Primary completion: phase 2 study in Hepatitis B, ChronicNCT07519330
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07519330Hepatitis B, Chronic · China | 2 | Recruiting | Feb 28, 2028 | 45 |
| NCT07515209Hepatitis B, Chronic · China | 1 | Completed | Dec 15, 2025 | 36 |
| NCT05275465Hepatitis B · Australia | 1 | Completed | Dec 29, 2022 | 33 |
How it is read
Names in the registry
- “HH-006”, 3 entries
Codes read as this program: HH006.
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 2 studies
- Hepatitis B, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.